Physician profile
Lisa Nijm
NPI 1427260975
$1,721,539.16
in general payments reported to CMS, 2019-2025
45 companies · $395K in 2025
The $395K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $148K · 2020: $92K · 2021: $214K · 2022: $166K · 2023: $289K · 2024: $417K · 2025: $395K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $559K · Consulting Fee: $330K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $79K · Honoraria: $68K · Travel and Lodging: $29K · Food and Beverage: $23K · Grant: $10K · Debt Forgiveness: $2,100 · Other payment types: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $558,675.00 |
| Consulting Fee | $330,058.85 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $79,243.26 |
| Honoraria | $68,350.00 |
| Travel and Lodging | $29,344.63 |
| Food and Beverage | $23,066.83 |
| Grant | $10,000.00 |
| Debt Forgiveness | $2,100.00 |
| Other payment types | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $729,174.45 | 2022-2025 | Envista Mx60 Iol, Xiidra, Miebo |
| Carl Zeiss Meditec, INC. | $150,669.88 | 2019-2025 | Visumax, Veracity Surgical, Quatera 700 |
| Alcon Vision LLC | $124,091.07 | 2019-2025 | Tryptyr, Eysuvis, Dailies Total1 |
| Novartis Pharmaceuticals Corporation | $119,591.26 | 2019-2023 | |
| Tearlab Corp | $80,117.27 | 2021-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61,613.19 | 2019-2021 | |
| Horizon Therapeutics Plc | $58,567.34 | 2019-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $51,158.88 | 2019-2025 | Cequa |
| Allergan, INC. | $48,670.69 | 2019-2022 | |
| Oyster Point Pharma, INC. | $40,828.59 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $38,842.71 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $36,006.05 | 2019-2024 | Tecnis Iol, Compact Intuitiv, Healon Duet Pro |
| Amgen INC. | $34,071.56 | 2024-2025 | Tepezza |
| Glaukos Corporation | $31,213.55 | 2022-2025 | Istent Supra Suprachoroidal Micro-Bypass Stent, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Idosetr |
| Ocular Therapeutix, INC. | $25,615.65 | 2019-2024 | Dextenza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $19,783.15 | 2025 | Purified Cortrophin Gel, Iluvien |
| Kala Pharmaceuticals, INC. | $14,468.60 | 2019-2022 | |
| Eyepoint US, INC. | $10,364.75 | 2019-2022 | |
| Thea Pharma INC. | $8,500.67 | 2022-2025 | Iyuzeh |
| Akorn Operating Company LLC | $8,250.00 | 2021 | |
| Harrow Eye, LLC | $6,877.01 | 2023-2025 | Vevye |
| Beaver-Visitec International, INC. | $5,163.33 | 2024-2025 | |
| Omeros Corporation | $3,550.37 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $2,471.66 | 2021-2025 | Syfovre |
| Nordic Pharma, INC. | $2,100.00 | 2024 | Lacrifill |
| Carl Zeiss Meditec USA, INC. | $2,021.17 | 2021-2025 | |
| Dompe US, INC. | $1,522.01 | 2019-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $1,200.00 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $1,076.99 | 2023-2024 | Tecnis Simplicity, Mentor Siltex Round Spectrum, Catalys System |
| Alcon Research LLC | $651.00 | 2023 | |
| Lumibird Medical INC. | $481.41 | 2025 | |
| Sight Sciences, INC. | $472.48 | 2019-2025 | Omni Surgical System, Tearcare System |
| Shire North American Group INC | $461.70 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $449.90 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $406.12 | 2022-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Haag-Streit USA, INC. | $232.54 | 2022-2023 | |
| Akorn, INC. | $199.26 | 2019-2020 | |
| Quidel Corporation | $146.11 | 2020-2021 | |
| Astellas Pharma US INC | $143.03 | 2024-2025 | Izervay |
| Mallinckrodt Enterprises LLC | $105.38 | 2019 | |
| Genentech USA, INC. | $59.82 | 2025 | |
| New World Medical,INC. | $56.35 | 2023 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Mallinckrodt Hospital Products INC. | $31.87 | 2022 | |
| Rxsight INC | $21.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,417.86 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Nijm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.